Safety and Efficacy of Panitumumab in the Treatment of Metastatic Colorectal Cancer

摘要: Therapies targeting epidermal growth factor receptor (EGFR) are a promising recent development in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is fully human anti-EGFR monoclonal antibody that competitively inhibits binding all known EGFR ligands, including and transforming alpha, to cells expressing EGFR. In patients with mCRC, panitumumab monotherapy has resulted favorable clinical responses, increases objective response rate, stable disease progression-free survival. also shown antitumor activity combination selected chemotherapy regimens. Responses improvements survival associated mCRC appear be confined whose tumors express wild-type KRAS. Therapy generally well tolerated; most common adverse events observed include skin-related toxicities, gastrointestinal hypomagnesemia. Infusion reactions rare, agent low immunogenicity.